Provided by Tiger Trade Technology Pte. Ltd.

Gain Therapeutics, Inc.

1.71
-0.0100-0.58%
Post-market: 1.750.0400+2.34%19:40 EDT
Volume:385.59K
Turnover:668.85K
Market Cap:74.63M
PE:-3.36
High:1.78
Open:1.75
Low:1.70
Close:1.72
52wk High:4.34
52wk Low:1.53
Shares:43.64M
Float Shares:42.34M
Volume Ratio:0.55
T/O Rate:0.91%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.5092
EPS(LYR):-0.6115
ROE:-268.30%
ROA:-95.51%
PB:6.61
PE(LYR):-2.80

Loading ...

Gain Therapeutics receives FDA clearance of GT-02287 IND application

TIPRANKS
·
Jun 30

Gain Therapeutics Wins FDA IND Clearance for Parkinson’s Drug Gt-02287 Phase 2 Trial

Reuters
·
Jun 30

Gain Therapeutics - FDA Decision Allows Initiation of Phase 2 for Gt-2287 in Parkinson's Disease

THOMSON REUTERS
·
Jun 30

Gain Therapeutics - Gt-2287 Phase 2 Clinical Development in U.S. Expected to Initiate During 3Q26

THOMSON REUTERS
·
Jun 30

Gain Therapeutics Shareholders Confirm Board and Auditor Choices

TIPRANKS
·
Jun 26

Gain Therapeutics CEO to speak at H.C. Wainwright Neuro Perspectives Summit

Reuters
·
Jun 10

Gain Therapeutics (GANX) Receives a Buy from H.C. Wainwright

TIPRANKS
·
Jun 09

Analysts Offer Insights on Healthcare Companies: Gain Therapeutics (GANX) and Travere Therapeutics (TVTX)

TIPRANKS
·
May 28

Shrader Reiterates Buy on GANX as Parkinson’s Data Strengthens GT-02287 Profile; $5 Price Target Maintained

TIPRANKS
·
May 27

Gain Therapeutics presents data from Phase 1b study of GT-02287

TIPRANKS
·
May 26

BRIEF-Gain Therapeutics Says MDS-UPDRS Scores Remain Stable After 150 Days Of GT-2287 Treatment

Reuters
·
May 26

Gain Therapeutics Inc - Mds-Updrs Scores Remain Stable After 150 Days of GT-2,287 Treatment

THOMSON REUTERS
·
May 26

Gain Therapeutics Inc - 4.8 Point Difference in Mds-Updrs Scores at Day 150 Between Glusph Groups

THOMSON REUTERS
·
May 26

Gain Therapeutics reports stable MDS-UPDRS scores at Day 150 in Phase 1b trial of Parkinson’s drug GT-02287

Reuters
·
May 26

Gain Therapeutics Presents Positive Interim Data from Phase 1b Clinical Study of GT-02287 at 3rd International GBA1 Meeting 2026

GlobeNewswire
·
May 26

Gain Therapeutics price target lowered to $8 from $10 at Roth Capital

TIPRANKS
·
May 13

Gain Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
May 12

Gain Therapeutics Q1 loss per share narrows

Reuters
·
May 11

Gain Therapeutics Q1 EPS $(0.13) Beats $(0.14) Estimate

Benzinga Earnings
·
May 11

Press Release: Gain Therapeutics Reports Financial Results for First Quarter 2026 and Provides Corporate Update

Dow Jones
·
May 11